1. Home
  2. DSGX vs ABVX Comparison

DSGX vs ABVX Comparison

Compare DSGX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Descartes Systems Group Inc. (The)

DSGX

Descartes Systems Group Inc. (The)

N/A

Current Price

$92.11

Market Cap

6.6B

Sector

Technology

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

N/A

Current Price

$87.60

Market Cap

7.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DSGX
ABVX
Founded
1981
2013
Country
Canada
France
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
7.7B
IPO Year
1999
2022

Fundamental Metrics

Financial Performance
Metric
DSGX
ABVX
Price
$92.11
$87.60
Analyst Decision
Buy
Strong Buy
Analyst Count
14
12
Target Price
$102.62
★ $163.58
AVG Volume (30 Days)
478.4K
★ 1.1M
Earning Date
12-02-2026
09-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.95
N/A
Revenue Next Year
$12.84
$1,695.54
P/E Ratio
$37.05
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$62.56
$69.81
52 Week High
$96.30
$148.83

Technical Indicators

Market Signals
Indicator
DSGX
ABVX
Relative Strength Index (RSI) 66.66 41.52
Support Level $69.79 $84.11
Resistance Level N/A $99.59
Average True Range (ATR) 2.51 3.73
MACD 0.77 0.76
Stochastic Oscillator 82.38 33.71

Price Performance

Historical Comparison
DSGX
ABVX

About DSGX Descartes Systems Group Inc. (The)

Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: